Biogen 3Q Revenues: $3.4 billion (+12%) 3Q Earnings: $1.4 billion (+18%) YTD Revenues: $9.9 billion (+11%) YTD Earnings: $3.5 billion (+24%) Comments: Multiple sclerosis (MS) revenues were relatively flat at $2.3 billion in the quarter, including approximately $137 million in royalties on the sales of OCREVUS (+112%). TECFIDERA sales were $1.1 billion, up 2% in the quarter. Avonex sales were down 10% to $482 million. TYSABRI sales were flat at $470 million. Revenue growth was driven in part...